drugset / Trial / NCT06671405

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

NCT06671405

Phase 1 Completed 59 enrolled AstraZeneca
Non-randomizedSequentialOpen-labelOther

Summary

An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered alone and in combination with AZD0780.

Timeline

Start
2024-09-25
Primary completion
2025-02-17
Completion
2025-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule 100 mg
Subject Carbamazepine Small molecule 200 mg
Subject Carbamazepine Small molecule 300 mg
Subject Itraconazole Small molecule
Subject Laroprovstat Small molecule
Subject Levonorgestrel Small molecule
Subject Midazolam Small molecule
Subject ethinyl estradiol Small molecule

Indications